David Krige
- Neurology top 5%
- Clinical Biochemistry top 5%
- Neurology top 10%
-
- Mitochondrial Function and Pathology 5
- Histone Deacetylase Inhibitors Research 5
-
- CAR-T cell therapy research 11
- Peptidase Inhibition and Analysis 7
- Cancer Immunotherapy and Biomarkers 6
-
- Cancer Research and Treatments 7
-
- Virus-based gene therapy research 6
-
- Multiple Myeloma Research and Treatments 4
- Co-authors
- Anthony H.V. SchapiraJonathan M. CooperC. D. MarsdenV. M. MannS. E. DanielShetal PatelDori HuertasGraham J. Kemp
- Partner nations
- United KingdomUnited StatesSpain
In The Last Decade
David Krige
32 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 78
- Neurology 396
- Cellular and Molecular Neuroscience 288
- Clinical Biochemistry 104
- Neurology 103
- Molecular Biology 636
Countries citing papers authored by David Krige
This map shows the geographic impact of David Krige's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Krige with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Krige more than expected).
Fields of papers citing papers by David Krige
This network shows the impact of papers produced by David Krige. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Krige. The network helps show where David Krige may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Krige, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 28 | |
| 2 | 2022 | 2 | |
| 3 | 2021 | 35 | |
| 4 | 2021 | 2 | |
| 5 | 2021 | 4 | |
| 6 | 2019 | 7 | |
| 7 | Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector IMCgp100 in advanced uveal melanoma | 2017 | 5 |
| 8 | A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma | 2015 | 3 |
| 9 | 2015 | 5 | |
| 10 | 2012 | 35 | |
| 11 | 2011 | 96 | |
| 12 | 2010 | 16 | |
| 13 | 2009 | 44 | |
| 14 | 1997 | 6 | |
| 15 | 1994 | 50 | |
| 16 | 1992 | 292 | |
| 17 | 1992 | 29 | |
| 18 | 1992 | 276 | |
| 19 | 1992 | 1 | |
| 20 | 1992 | 9 |
About David Krige
David Krige is a scholar working on Biotechnology, Oncology, Hematology, Cancer Research and Clinical Biochemistry, having authored 32 papers that have together received 1.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (11 papers), Cancer Research and Treatments (7 papers), Peptidase Inhibition and Analysis (7 papers), Virus-based gene therapy research (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Mitochondrial Function and Pathology (5 papers), Histone Deacetylase Inhibitors Research (5 papers) and Multiple Myeloma Research and Treatments (4 papers). The work is most often cited by research in Neurology (396 citations), Cellular and Molecular Neuroscience (288 citations), Clinical Biochemistry (104 citations), Neurology (103 citations) and Molecular Biology (636 citations). David Krige has collaborated with scholars based in United Kingdom, United States and Spain. Frequent co-authors include Anthony H.V. Schapira, Jonathan M. Cooper, C. D. Marsden, V. M. Mann, S. E. Daniel, Shetal Patel, Dori Huertas, Graham J. Kemp, Alfredo Martı́nez and Deborah H. Brotherton. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Blood, Biochimica et Biophysica Acta (BBA) - Bioenergetics and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.